Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE4
113 participants
INTERVENTIONAL
2010-08-31
2011-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Vitamin D Intervention in Infants
NCT01723852
Vitamin D Intervention in Infants - 6 Years Follow-up (VIDI2)
NCT04302987
Effect of Vitamin D in Diets of Preterm Infants
NCT01698840
Vitamin D Supplementation in Pediatrics. Oral or Parenteral! D2 or D3
NCT06176157
Effect of Vitamin D3 Supplementation in Children From 12 to 30 Months of Age.
NCT03544671
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
PREVENTION
QUADRUPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Vitamin D3 10µg
cholecalciferol (D3)
10µg (400 IU) orally daily for 10 weeks
Vitamin D3 30µg
cholecalciferol (D3)
30µg (1200 IU) orally daily for 10 weeks
Vitamin D3 40µg
cholecalciferol (D3)
40µg (1600 IU) orally daily for 10 weeks
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
cholecalciferol (D3)
10µg (400 IU) orally daily for 10 weeks
cholecalciferol (D3)
30µg (1200 IU) orally daily for 10 weeks
cholecalciferol (D3)
40µg (1600 IU) orally daily for 10 weeks
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* healthy infants born at term and appropriate for gestational age
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Helsinki
OTHER
Helsinki University Central Hospital
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Helsinki University Central Hospital
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Sture Andersson, MD, PhD
Role: PRINCIPAL_INVESTIGATOR
Helsinki University Central Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Hospital for Children and Adolescents, Helsinki University Central Hospital
Helsinki, , Finland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2009-015940-40
Identifier Type: EUDRACT_NUMBER
Identifier Source: secondary_id
T1040D0038
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.